CN117769555A - 喜树碱衍生物、其药物组合物及其应用 - Google Patents

喜树碱衍生物、其药物组合物及其应用 Download PDF

Info

Publication number
CN117769555A
CN117769555A CN202280054490.6A CN202280054490A CN117769555A CN 117769555 A CN117769555 A CN 117769555A CN 202280054490 A CN202280054490 A CN 202280054490A CN 117769555 A CN117769555 A CN 117769555A
Authority
CN
China
Prior art keywords
reaction
compound
added
group
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280054490.6A
Other languages
English (en)
Chinese (zh)
Inventor
李桢
唐锋
付雅媛
刘力锋
赵春艳
唐任宏
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiansheng Zaiming Pharmaceutical Co ltd
Original Assignee
Xiansheng Zaiming Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiansheng Zaiming Pharmaceutical Co ltd filed Critical Xiansheng Zaiming Pharmaceutical Co ltd
Publication of CN117769555A publication Critical patent/CN117769555A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280054490.6A 2021-08-19 2022-08-19 喜树碱衍生物、其药物组合物及其应用 Pending CN117769555A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021109553645 2021-08-19
CN202110955364 2021-08-19
CN202111515247 2021-12-13
CN2021115152473 2021-12-13
CN202210515797 2022-05-12
CN2022105157973 2022-05-12
PCT/CN2022/113499 WO2023020605A1 (zh) 2021-08-19 2022-08-19 喜树碱衍生物、其药物组合物及其应用

Publications (1)

Publication Number Publication Date
CN117769555A true CN117769555A (zh) 2024-03-26

Family

ID=85239565

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280054490.6A Pending CN117769555A (zh) 2021-08-19 2022-08-19 喜树碱衍生物、其药物组合物及其应用

Country Status (8)

Country Link
US (1) US20250270227A1 (https=)
EP (1) EP4389752A4 (https=)
JP (1) JP2024532768A (https=)
KR (1) KR20240049583A (https=)
CN (1) CN117769555A (https=)
AU (1) AU2022330892A1 (https=)
CA (1) CA3228345A1 (https=)
WO (1) WO2023020605A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
KR20240149823A (ko) * 2023-04-06 2024-10-15 주식회사 피노바이오 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
CN120858098A (zh) * 2023-05-04 2025-10-28 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
WO2024227439A1 (zh) * 2023-05-04 2024-11-07 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
WO2025153001A1 (zh) * 2024-01-17 2025-07-24 北京泰德制药股份有限公司 含有噻唑[5,4-b]吡啶结构的抗体偶联药物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540099B1 (en) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
CN1036197C (zh) * 1992-01-28 1997-10-22 格拉克索有限公司 水溶性喜树碱衍生物
JPH1171280A (ja) * 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TWI851577B (zh) * 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
EP4628165A3 (en) * 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
EP4257154A4 (en) * 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
IL308734A (en) * 2021-05-27 2024-01-01 Zymeworks Bc Inc Camptothecin analogues, conjugates and methods of use
US20240376120A1 (en) * 2021-09-01 2024-11-14 Shanghai Best-Link Bioscience, Llc Camptothecin compound, preparation method therefor and use thereof
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用

Also Published As

Publication number Publication date
CA3228345A1 (en) 2023-02-23
US20250270227A1 (en) 2025-08-28
AU2022330892A1 (en) 2024-03-21
EP4389752A4 (en) 2025-08-20
JP2024532768A (ja) 2024-09-10
WO2023020605A1 (zh) 2023-02-23
KR20240049583A (ko) 2024-04-16
EP4389752A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
CN117769555A (zh) 喜树碱衍生物、其药物组合物及其应用
CN114981268B (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
CN113631557B (zh) Jak激酶抑制剂及其制备方法和在医药领域的应用
JP2025532125A (ja) 新規なテトラヘテロサイクル化合物
CN112745335B (zh) 一种三并杂环化合物及其用途
CN112300153B (zh) 一种杂环化合物、药物组合物和用途
CN105461714B (zh) 并环类pi3k抑制剂
CN101305010A (zh) Raf抑制剂化合物及其用法
TW202521549A (zh) 一種稠環化合物及在ｋｒａｓ抑制劑方面的應用
CN112851663B (zh) 一种并杂环化合物及其用途
TW202523324A (zh) 一種稠環化合物及應用
KR102866724B1 (ko) 아자헤테로아릴 화합물 및 이의 용도
CA3161739A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
CN115038707B (zh) 氮杂卓类稠环化合物及其医药用途
JP2022000455A (ja) フラバグリン誘導体
CN112707905A (zh) 一种三并杂环化合物及其制备方法和用途
CN113286796A (zh) 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
JP2022554385A (ja) Ｗｄｒ５阻害剤及び調節剤
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN113248497B (zh) 用作fgfr4抑制剂的稠环衍生物
EP4378943A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CN116867779A (zh) 用于癌症治疗的KRas抑制剂
CN114920738B (zh) 用于癌症治疗的KRas抑制剂
WO2025148870A1 (zh) Ras抑制剂
JP7688954B2 (ja) イミダゾピリダジン系誘導体、その製造方法、医薬組成物及び使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Country or region after: China

Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311

Applicant after: Hainan Xiansheng Zaiming Pharmaceutical Co.,Ltd.

Address before: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311

Applicant before: Xiansheng Zaiming Pharmaceutical Co.,Ltd.

Country or region before: China

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: China

Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311

Applicant after: Xiandeng Medical Co.,Ltd.

Address before: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311

Applicant before: Hainan Xiansheng Zaiming Pharmaceutical Co.,Ltd.

Country or region before: China

CB02 Change of applicant information